Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- AFFINITY THERAPEUTICS, LLC
- Proposal award date
- 2017-04-01
- Contract end date
- 2019-03-31
- UEI
- MVSNZ6XDQAE9
- Solicitation number
- PA16-302
- Topic code
- NHLBI
Research abstract
Abstract Summary
Arteriovenous fistulas AVFs are the preferred vascular access mode for hemodialysis patients but
of AVFs fail to mature and only of mature AVFs are patent after year Vascular access
failure including AVFs results from neointimal hyperplasia and contributes to andgt $ billion USD annual
costs from vascular access failure including of hemodialysis patient hospitalizations Systemic statin
treatment is known to help prevent neointimal hyperplasia in arterial bypass grafting and recent study of
patients showed a reduction in AVF failure that was strongly tied to statin identity and dose
Recent evidence from Dr Sanjay Misra s lab shows that systemic statins were able to significantly reduce
neointimal hyperplasia in a mouse chronic kidney disease AVF model Affinity aims to create statin loaded
microparticles that can be injected into the adventitia of the venous outflow tract of the AVF to prevent
neointimal hyperplasia by locally delivering statins over the course of weeks thereby eliminating potential
side effects and increasing efficacy of statin action Our long term goal is to develop injectable
microparticles capable of preventing neointimal hyperplasia The objective of this proposal is to produce
statin loaded injectable microparticles to prevent AVF failure due to neointimal hyperplasia The central
hypothesis is that localized delivery of statins over the course of several weeks will increase the lumen
area of the venous outflow tract by preventing fibroblast conversion to myofibroblasts and preventing
proliferation of smooth muscle cells thereby decreasing neointimal area in the venous outflow tract This
work will be accomplished in three aims Validate statin loading and delivery in vitro Validate statin
delivery on a model of myofibroblast differentiation using hypoxic fibroblasts in vitro and Minimize
venous neointimal hyperplasia following AVF creation in vivo
Our proposed work is innovative using injectable microparticles to deliver statins directly to the venous
outflow tract tissue to prevent neointimal hyperplasia We use a novel approach to achieve high loading
and long term sustained delivery of statins in a mode that eliminates any potential systemic side effects
The expected outcomes include injectable microparticles capable of release statin for andgt days in vitro
and preventing neointimal hyperplasia for at least days in vivo These results will positively impact the
field of vascular access by decreasing failure rates for both AVFs and AV grafts due to neointimal
hyperplasia Future work in Phase II will translate these statin loaded injectable microparticles from this
Phase I proof of concept work into a statistically powerful study in pigs where the vasculature and
hemodynamics are most similar to those in humans Project Narrative
This proposal is critically concerned with the issue of public health in that its long term goal is to
prevent primary failure of vascular access in hemodialysis patients due to neointimal
hyperplasia Specifically we hope to accomplish this goal using an affinity based drug delivery
system to deliver drug over a period of weeks The short term goals are to develop a
microparticle formulation from affinity based polymers and to assess the efficacy of simvastatin
delivery in a murine arteriovenous fistula in vivo model
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
4 SBIR/STTR records share this UEI (2012–2017). Reported award amounts total $1,151,749. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services, National Science Foundation
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards